BlueScope left investors disappointed this morning with a 64% lower net profit
Of this morning’s 1HY23 results, Bluescope (ASX:BSL) was the one that left investors the most disappointed, if the ~7% share price decline is any guide. The company’s net profit and EBIT both declined by over 60%, missing analysts expectations.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Bluescope’s EBIT and net profit fell by over 60%
1HY23 was a difficult market for steel with weather related disruptions in building and construction activity.
Although Bluescope’s revenue was only down 1.2% from 12 months ago (at $9.3bn), the company’s EBIT and net profit came in at 60% lower than 12 months ago – at $834.4m and $598.8m respectively. The company’s ROIC also fell from 43.7% to 23.4%.
On a more positive note, the company’s net cash grew $367m to $606m and its free cash flow (operaitng cash flow less capex) was up $63m to $751m. Its interim dividend was unchanged at 25cps, representing a 2.7% yield on an annualised basis.
Shares fell by over 7% in this morning’s trade, the most of any company releasing 1HY23 results.
Bluescope (ASX:BSL) share price chart, log scale (Source: TradingView)
Bluescope says the long-term outlook remains positive
Despite the negative results, Bluescope told shareholders it was well positioned for the long-term.
The company said the global green revolution was driving demand for steel as a critical input towards particular types of infrastructure, particularly renewable energy and e-commerce infrastructure.
It also noted consolidation and rationalisation in the US steel industry and a focus on emissions reduction by China’s steel industry supported supply-side discipline.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now
FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic…
How Nuclear Energy Became the World’s Most Feared Energy Source
Why Nuclear Energy Still Scares Us and What Really Went Wrong Many investors may remember periods when nuclear energy captured…
Dateline Resources (ASX:DTR) From 60c Highs to Hard Lessons
A Rare Earth Story the Market Loved Then Questioned For investors who have followed Dateline Resources (ASX:DTR), the past year…